NCT01104480

Tocilizumab for Relapsing Polychondritis

Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: McMaster Children's Hospital · Academic / Other
• Sex: Male
• Age: 12 Years – 15 Years
• Healthy volunteers: Not accepted

Summary

This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.

Conditions

• Relapsing Polychondritis

Interventions

Type	Name	Description
DRUG	Tocilizumab	Tocilizumab 8mg/kg every 2 weeks given by IV infusion

Timeline

• Start date: 2010-05-01
• Primary completion: 2010-07-01
• Completion: 2012-05-01
• First posted: 2010-04-15
• Last updated: 2014-05-13

Locations

1 site across 1 country: Canada